Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Using co-occurrence network topology in assessing ecological stress in benthic macroinvertebrate communities.

Simons AL, Mazor R, Theroux S.

Ecol Evol. 2019 Oct 29;9(22):12789-12801. doi: 10.1002/ece3.5751. eCollection 2019 Nov.

2.

Prognostic markers and assessment of a previously published clinical severity index in 109 hospitalised dogs with acute presentation of pancreatitis.

Kuzi S, Mazor R, Segev G, Nivy R, Mazaki-Tovi M, Chen H, Rimer D, Duneyevitz A, Yas E, Lavy E, Aroch I.

Vet Rec. 2019 Oct 29. pii: vetrec-2019-105364. doi: 10.1136/vr.105364. [Epub ahead of print]

PMID:
31662578
3.

Using alpha, beta, and zeta diversity in describing the health of stream-based benthic macroinvertebrate communities.

Simons AL, Mazor R, Stein ED, Nuzhdin S.

Ecol Appl. 2019 Jun;29(4):e01896. doi: 10.1002/eap.1896. Epub 2019 May 3.

PMID:
31051052
4.

Enteral Tranexamic Acid Decreases Proteolytic Activity in the Heart in Acute Experimental Hemorrhagic Shock.

Aletti F, Santamaria M, Chin K, Mazor R, Kistler EB.

J Cardiovasc Pharmacol Ther. 2019 Sep;24(5):484-493. doi: 10.1177/1074248419841630. Epub 2019 Apr 29.

PMID:
31035788
5.

SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.

Leshem Y, King EM, Mazor R, Reiter Y, Pastan I.

Toxins (Basel). 2018 Nov 14;10(11). pii: E470. doi: 10.3390/toxins10110470.

6.

Bleeding emergencies in neonatal and paediatric patients: improving the quality of care using simulation.

Delaney M, Roberts J, Mazor R, Townsend-McCall D, Saifee NH, Pagano MB, Matthews DC, Stone K.

Transfus Med. 2018 Dec;28(6):405-412. doi: 10.1111/tme.12562. Epub 2018 Oct 16.

PMID:
30325081
7.

Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.

Mazor R, King E, Pastan I.

Cell Immunol. 2018 Dec;334:38-41. doi: 10.1016/j.cellimm.2018.08.016. Epub 2018 Aug 28.

8.

Cleavage of the leptin receptor by matrix metalloproteinase-2 promotes leptin resistance and obesity in mice.

Mazor R, Friedmann-Morvinski D, Alsaigh T, Kleifeld O, Kistler EB, Rousso-Noori L, Huang C, Li JB, Verma IM, Schmid-Schönbein GW.

Sci Transl Med. 2018 Aug 22;10(455). pii: eaah6324. doi: 10.1126/scitranslmed.aah6324.

PMID:
30135249
9.

Added Value of Fetal MRI in the Evaluation of Fetal Anomalies of the Corpus Callosum: A Retrospective Analysis of 78 Cases.

Manevich-Mazor M, Weissmann-Brenner A, Bar Yosef O, Hoffmann C, Mazor RD, Mosheva M, Achiron RR, Katorza E.

Ultraschall Med. 2018 Oct;39(5):513-525. doi: 10.1055/s-0043-113820. Epub 2018 Jun 7.

PMID:
29879745
10.

Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.

Mazor R, King EM, Pastan I.

Am J Pathol. 2018 Aug;188(8):1736-1743. doi: 10.1016/j.ajpath.2018.04.016. Epub 2018 Jun 2. Review.

11.

Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering.

Kaplan G, Mazor R, Lee F, Jang Y, Leshem Y, Pastan I.

Mol Cancer Ther. 2018 Jul;17(7):1486-1493. doi: 10.1158/1535-7163.MCT-17-1041. Epub 2018 Apr 25.

12.

Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.

King EM, Mazor R, Çuburu N, Pastan I.

J Immunol. 2018 Mar 15;200(6):2038-2045. doi: 10.4049/jimmunol.1701430. Epub 2018 Feb 5.

13.

Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.

Mazor R, King EM, Onda M, Cuburu N, Addissie S, Crown D, Liu XF, Kishimoto TK, Pastan I.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E733-E742. doi: 10.1073/pnas.1717063115. Epub 2018 Jan 8. Review.

14.

ICAMs support B cell interactions with T follicular helper cells and promote clonal selection.

Zaretsky I, Atrakchi O, Mazor RD, Stoler-Barak L, Biram A, Feigelson SW, Gitlin AD, Engelhardt B, Shulman Z.

J Exp Med. 2017 Nov 6;214(11):3435-3448. doi: 10.1084/jem.20171129. Epub 2017 Sep 22.

15.

High throughput in vitro and in vivo screening of inland waters of Southern California.

Mehinto AC, VanDervort DR, Lao W, He G, Denison MS, Vliet SM, Volz DC, Mazor RD, Maruya KA.

Environ Sci Process Impacts. 2017 Sep 20;19(9):1142-1149. doi: 10.1039/c7em00170c.

PMID:
28612856
16.

Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.

Mazor R, Kaplan G, Park D, Jang Y, Lee F, Kreitman R, Pastan I.

Cell Immunol. 2017 Mar;313:59-66. doi: 10.1016/j.cellimm.2017.01.003. Epub 2017 Jan 5.

17.

Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin.

Mazor R, Addissie S, Jang Y, Tai CH, Rose J, Hakim F, Pastan I.

AAPS J. 2017 Jan;19(1):117-129. doi: 10.1208/s12248-016-9986-y. Epub 2016 Oct 27.

PMID:
27796910
18.

Corrigendum to "Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects" [J. Autoimmun. 47C (2013) 1-16].

Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y.

J Autoimmun. 2016 Aug;72:126. doi: 10.1016/j.jaut.2016.05.011. Epub 2016 Jun 3. No abstract available.

PMID:
27269045
19.

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.

Mazor R, Onda M, Park D, Addissie S, Xiang L, Zhang J, Hassan R, Pastan I.

Oncotarget. 2016 May 24;7(21):29916-26. doi: 10.18632/oncotarget.9171.

20.

The inter-observer variability of breast density scoring between mammography technologists and breast radiologists and its effect on the rate of adjuvant ultrasound.

Mazor RD, Savir A, Gheorghiu D, Weinstein Y, Abadi-Korek I, Shabshin N.

Eur J Radiol. 2016 May;85(5):957-62. doi: 10.1016/j.ejrad.2016.02.023. Epub 2016 Mar 3.

PMID:
27130056
21.

Immunogenicity of therapeutic recombinant immunotoxins.

Mazor R, Onda M, Pastan I.

Immunol Rev. 2016 Mar;270(1):152-64. doi: 10.1111/imr.12390. Review.

22.

Heparin Interaction with the Primed Polymorphonuclear Leukocyte CD11b Induces Apoptosis and Prevents Cell Activation.

Cohen-Mazor M, Mazor R, Kristal B, Kistler EB, Ziv I, Chezar J, Sela S.

J Immunol Res. 2015;2015:751014. doi: 10.1155/2015/751014. Epub 2015 Dec 27.

23.
24.

In vivo analysis of intestinal permeability following hemorrhagic shock.

Alsaigh T, Chang M, Richter M, Mazor R, Kistler EB.

World J Crit Care Med. 2015 Nov 4;4(4):287-95. doi: 10.5492/wjccm.v4.i4.287. eCollection 2015 Nov 4.

25.

Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.

Mazor R, Crown D, Addissie S, Jang Y, Kaplan G, Pastan I.

Cell Mol Immunol. 2017 May;14(5):432-442. doi: 10.1038/cmi.2015.91. Epub 2015 Oct 19.

26.

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.

Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, Hassan R, Pastan I.

Mol Cancer Ther. 2015 Dec;14(12):2789-96. doi: 10.1158/1535-7163.MCT-15-0532. Epub 2015 Oct 6.

27.

Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.

Mazor R, Tai CH, Lee B, Pastan I.

J Immunol Methods. 2015 Oct;425:10-20. doi: 10.1016/j.jim.2015.06.003. Epub 2015 Jun 6.

28.

Antithrombin concentrates use in children on extracorporeal membrane oxygenation: a retrospective cohort study.

Wong TE, Delaney M, Gernsheimer T, Matthews DC, Brogan TV, Mazor R, McMullan DM, Reiner AP, Konkle BA.

Pediatr Crit Care Med. 2015 Mar;16(3):264-9. doi: 10.1097/PCC.0000000000000322.

PMID:
25581634
29.

Cellular and molecular basis of Venous insufficiency.

Pocock ES, Alsaigh T, Mazor R, Schmid-Schönbein GW.

Vasc Cell. 2014 Dec 12;6(1):24. doi: 10.1186/s13221-014-0024-5. eCollection 2014.

30.

Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.

Mazor RD, Manevich-Mazor M, Kesler A, Aizenstein O, Eshed I, Jaffe R, Pessach Y, Goldberg I, Sprecher E, Yaish I, Gural A, Ganzel C, Shoenfeld Y.

BMC Med. 2014 Dec 1;12:221. doi: 10.1186/s12916-014-0221-3.

31.

Correspondence of biological condition models of California streams at statewide and regional scales.

May JT, Brown LR, Rehn AC, Waite IR, Ode PR, Mazor RD, Schiff KC.

Environ Monit Assess. 2015 Jan;187(1):4086. doi: 10.1007/s10661-014-4086-x. Epub 2014 Nov 11.

32.

[Erdheim-Chester disease].

Mazor RD, Shoenfeld Y.

Harefuah. 2014 Jul;153(7):389-91, 434, 433. Hebrew.

PMID:
25189027
33.

Elastase and cathepsin G from primed leukocytes cleave vascular endothelial cadherin in hemodialysis patients.

Cohen-Mazor M, Mazor R, Kristal B, Sela S.

Biomed Res Int. 2014;2014:459640. doi: 10.1155/2014/459640. Epub 2014 May 4.

34.

Removing T-cell epitopes with computational protein design.

King C, Garza EN, Mazor R, Linehan JL, Pastan I, Pepper M, Baker D.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8577-82. doi: 10.1073/pnas.1321126111. Epub 2014 May 19.

35.

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.

Mazor R, Eberle JA, Hu X, Vassall AN, Onda M, Beers R, Lee EC, Kreitman RJ, Lee B, Baker D, King C, Hassan R, Benhar I, Pastan I.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8571-6. doi: 10.1073/pnas.1405153111. Epub 2014 May 5.

36.

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects.

Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y.

J Autoimmun. 2013 Dec;47:1-16. doi: 10.1016/j.jaut.2013.10.004. Epub 2013 Nov 13. Review.

PMID:
24238833
37.

Erdheim-Chester Disease: a comprehensive review of the literature.

Mazor RD, Manevich-Mazor M, Shoenfeld Y.

Orphanet J Rare Dis. 2013 Sep 8;8:137. doi: 10.1186/1750-1172-8-137. Review.

38.

Identifying reference conditions and quantifying biological variability within benthic macroinvertebrate communities in perennial and non-perennial northern California streams.

Lunde KB, Cover MR, Mazor RD, Sommers CA, Resh VH.

Environ Manage. 2013 Jun;51(6):1262-73. doi: 10.1007/s00267-013-0057-1. Epub 2013 Apr 26.

PMID:
23620068
39.

Examining palliative care team involvement in automatic consultations for children on extracorporeal life support in the pediatric intensive care unit.

Doorenbos AZ, Starks H, Bourget E, McMullan DM, Lewis-Newby M, Rue TC, Lindhorst T, Aisenberg E, Oman N, Curtis JR, Hays R; Seattle Ethics in ECLS (SEE) Consortium, Clark JD, Baden HP, Brogan TV, Di Gennaro JL, Mazor R, Roberts JS, Turnbull J, Wilfond BS.

J Palliat Med. 2013 May;16(5):492-5. doi: 10.1089/jpm.2012.0536. Epub 2013 Mar 29.

40.

Evaluating ethanol-based sample preservation to facilitate use of DNA barcoding in routine freshwater biomonitoring programs using benthic macroinvertebrates.

Stein ED, White BP, Mazor RD, Miller PE, Pilgrim EM.

PLoS One. 2013;8(1):e51273. doi: 10.1371/journal.pone.0051273. Epub 2013 Jan 4.

41.

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.

Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, Pastan I.

Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3597-603. doi: 10.1073/pnas.1218138109. Epub 2012 Dec 3.

42.

Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells.

Mazor R, Alsaigh T, Shaked H, Altshuler AE, Pocock ES, Kistler EB, Karin M, Schmid-Schönbein GW.

J Biol Chem. 2013 Jan 4;288(1):598-607. doi: 10.1074/jbc.M112.417451. Epub 2012 Nov 15.

43.

Erdheim-Chester disease: an orphan condition seeking treatment.

Mazor RD, Kesler A, Shoenfeld Y.

Isr Med Assoc J. 2012 Jun;14(6):388-9. No abstract available.

44.

Use of venovenous extracorporeal life support in pediatric patients for cardiac indications: a review of the Extracorporeal Life Support Organization registry.

Kim K, Mazor RL, Rycus PT, Brogan TV.

Pediatr Crit Care Med. 2012 May;13(3):285-9. doi: 10.1097/PCC.0b013e31822f1586.

PMID:
21926665
45.

Bridging children of all sizes to cardiac transplantation: the initial multicenter North American experience with the Berlin Heart EXCOR ventricular assist device.

Morales DL, Almond CS, Jaquiss RD, Rosenthal DN, Naftel DC, Massicotte MP, Humpl T, Turrentine MW, Tweddell JS, Cohen GA, Kroslowitz R, Devaney EJ, Canter CE, Fynn-Thompson F, Reinhartz O, Imamura M, Ghanayem NS, Buchholz H, Furness S, Mazor R, Gandhi SK, Fraser CD Jr.

J Heart Lung Transplant. 2011 Jan;30(1):1-8. doi: 10.1016/j.healun.2010.08.033.

PMID:
21145473
46.

Minimizing bleeding associated with mechanical circulatory support following pediatric heart surgery.

McMullan DM, Emmert JA, Permut LC, Mazor RL, Jeffries HE, Parrish AR, Baden HP, Cohen GA.

Eur J Cardiothorac Surg. 2011 Mar;39(3):392-7. doi: 10.1016/j.ejcts.2010.07.027.

PMID:
20801051
47.

Tumor necrosis factor-alpha: a possible priming agent for the polymorphonuclear leukocyte-reduced nicotinamide-adenine dinucleotide phosphate oxidase in hypertension.

Mazor R, Itzhaki O, Sela S, Yagil Y, Cohen-Mazor M, Yagil C, Kristal B.

Hypertension. 2010 Feb;55(2):353-62. doi: 10.1161/HYPERTENSIONAHA.109.144154. Epub 2010 Jan 11.

PMID:
20065151
48.

Bioassessment tools in novel habitats: an evaluation of indices and sampling methods in low-gradient streams in California.

Mazor RD, Schiff K, Ritter K, Rehn A, Ode P.

Environ Monit Assess. 2010 Aug;167(1-4):91-104. doi: 10.1007/s10661-009-1033-3. Epub 2009 Jun 24.

PMID:
19551481
49.

Long-term variability in bioassessments: a twenty-year study from two northern California streams.

Mazor RD, Purcell AH, Resh VH.

Environ Manage. 2009 Jun;43(6):1269-86. doi: 10.1007/s00267-009-9294-8. Epub 2009 Apr 21.

50.

Increased levels of numerical chromosome aberrations after in vitro exposure of human peripheral blood lymphocytes to radiofrequency electromagnetic fields for 72 hours.

Mazor R, Korenstein-Ilan A, Barbul A, Eshet Y, Shahadi A, Jerby E, Korenstein R.

Radiat Res. 2008 Jan;169(1):28-37.

PMID:
18159938

Supplemental Content

Support Center